三生製藥早盤持續上漲逾5% 近日與輝瑞達成重磅交易

新浪港股

05-21

熱點欄目自選股數據中心行情中心資金流向模擬交易

客戶端

　　三生製藥（01530）早盤高開，股價現漲5.06，現報20.15港元，成交額5.18億港元。

　　三生製藥公告稱，其與輝瑞公司就前者自主研發的PD-1/VEGF雙特異性抗體SSGJ-707簽訂了獨家許可協議。輝瑞將獲得SSGJ-707在全球（不包括中國內地）開發、生產和商業化的獨家權利。三生製藥將獲得12.5億美元的首付款，以及最高可達48億美元的開發、註冊及銷售里程碑付款，外加基於產品在許可地區淨銷售額的梯度雙位數百分比提成。同時擁有中國區商業化選擇權。同時，輝瑞將以30日成交量加權平均價，認購三生製藥價值1億美元的新發普通股。

海量資訊、精準解讀，盡在新浪財經APP

責任編輯：盧昱君

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2537673912"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537673912\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2537673912?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-05-21 09:43","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2537673912","market":"hk","top_or_hot":-1,"title":"三生製藥早盤持續上漲逾5% 近日與輝瑞達成重磅交易","media":"新浪港股","content":"<html><body><div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/n/hk/min/640x360xxfhd/01530.png\"/>\n</div>\n<div>\n<div>\n<span>熱點欄目</span>\n<s></s>\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n</div>\n客戶端\n</div>\n</div>\n<p>　　<span><a href=\"https://laohu8.com/S/01530\">三生製藥</a></span><span></span>（01530）早盤高開，股價現漲5.06，現報20.15港元，成交額5.18億港元。</p>\n<p>　　三生製藥公告稱，其與<a href=\"https://laohu8.com/S/PFE\">輝瑞</a>公司就前者自主研發的PD-1/VEGF雙特異性抗體SSGJ-707簽訂了獨家許可協議 。輝瑞將獲得SSGJ-707在全球（不包括中國內地）開發、生產和商業化的獨家權利 。三生製藥將獲得12.5億美元的首付款，以及最高可達48億美元的開發、註冊及銷售里程碑付款，外加基於產品在許可地區淨銷售額的梯度雙位數百分比提成 。同時擁有中國區商業化選擇權。同時，輝瑞將以30日成交量加權平均價，認購三生製藥價值1億美元的新發普通股 。</p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：盧昱君 </p>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>三生製藥早盤持續上漲逾5% 近日與輝瑞達成重磅交易</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n三生製藥早盤持續上漲逾5% 近日與輝瑞達成重磅交易\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">新浪港股</strong><span class=\"h-time small\">2025-05-21 09:43</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/n/hk/min/640x360xxfhd/01530.png\"/>\n</div>\n<div>\n<div>\n<span>熱點欄目</span>\n<s></s>\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n</div>\n客戶端\n</div>\n</div>\n<p>　　<span><a href=\"https://laohu8.com/S/01530\">三生製藥</a></span><span></span>（01530）早盤高開，股價現漲5.06，現報20.15港元，成交額5.18億港元。</p>\n<p>　　三生製藥公告稱，其與<a href=\"https://laohu8.com/S/PFE\">輝瑞</a>公司就前者自主研發的PD-1/VEGF雙特異性抗體SSGJ-707簽訂了獨家許可協議 。輝瑞將獲得SSGJ-707在全球（不包括中國內地）開發、生產和商業化的獨家權利 。三生製藥將獲得12.5億美元的首付款，以及最高可達48億美元的開發、註冊及銷售里程碑付款，外加基於產品在許可地區淨銷售額的梯度雙位數百分比提成 。同時擁有中國區商業化選擇權。同時，輝瑞將以30日成交量加權平均價，認購三生製藥價值1億美元的新發普通股 。</p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：盧昱君 </p>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-05-21/doc-inexhsqn8240028.shtml\">新浪港股</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生製藥","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-05-21/doc-inexhsqn8240028.shtml","article_id":"2537673912","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537673912","pubTimestamp":1747791780,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"　　三生製藥早盤高開，股價現漲5.06，現報20.15港元，成交額5.18億港元。　　三生製藥公告稱，其與輝瑞公司就前者自主研發的PD-1/VEGF雙特異性抗體SSGJ-707簽訂了獨家許可協議 。三生製藥將獲得12.5億美元的首付款，以及最高可達48億美元的開發、註冊及銷售里程碑付款，外加基於產品在許可地區淨銷售額的梯度雙位數百分比提成 。同時，輝瑞將以30日成交量加權平均價，認購三生製藥價值1億美元的新發普通股 。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01530":"三生制药","BK1593":"医美概念股","BK4581":"高盛持仓","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999002232.USD":"Allianz Global High Payout USD","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SG9999001176.USD":"United Global Healthcare Acc USD","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","BK4599":"减肥药","BK4592":"伊斯兰概念","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0122379950.USD":"贝莱德世界健康科学A2","BK1583":"高瓴概念","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4588":"碎股","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","BK1161":"生物科技"},"translate_title":"3SBio continued to rise more than 5% in early trading and recently reached a blockbuster deal with Pfizer","themeId":"32bd8857c93003e7757eccf5ff11c4fd","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"熱點欄目\n\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n\n客户端\n\n\n　　三生製藥（01530）早盤高開，股價現漲5.06，現報20.15港元，成交額5.18億港元。\n　　三生製藥公告稱，其與輝瑞公司就前者自主研發的PD-1/VEGF雙特異性抗體SSGJ-707簽訂了獨家許可協議 。輝瑞將獲得SSGJ-707在全球（不包括中國內地）開發、生產和商業化的獨家權利 。三生製藥將獲得12.5億美元的首付款，以及最高可達48億美元的開發、註冊及銷售里程碑付款，外加基於產品在許可地區淨銷售額的梯度雙位數百分比提成 。同時擁有中國區商業化選擇權。同時，輝瑞將以30日成交量加權平均價，認購三生製藥價值1億美元的新發普通股 。\n\n\n\n海量資訊、精準解讀，盡在新浪財經APP\n\n責任編輯：盧昱君","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}